Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 4/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 3/20 | 0.33 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.33 |
| ▸ | SI | P14410 | 3/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.33 |
| ▸ | F12 | P00748 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598226 | 0.82 | DGAT1 (0.49) | KCNMA1GAAKDM4EMGAMAMY1A | |
| SCHEMBL29031456 | 0.76 | GLA (0.38) | GLATHRBKMOKCNMA1GAA | |
| SCHEMBL29467313 | 0.68 | KMT2A (0.40) | GLATHRBKMOGAACYP2C19 | |
| SCHEMBL1069721 | 0.68 | KMT2A (0.40) | GLATHRBKMOGAACYP2C19 | |
| SCHEMBL15771522 | 0.68 | KMT2A (0.40) | GLATHRBKMOGAACYP2C19 | |
| SCHEMBL27380658 | 0.67 | KMO (0.57) | GLATHRBKMOKCNMA1GAA | |
| SCHEMBL15020417 | 0.66 | KMO (0.40) | GLATHRBKMOGAACYP2C19 | |
| SCHEMBL12593994 | 0.65 | KMO (0.49) | GLATHRBKMOKCNMA1GAA | |
| SCHEMBL419612 | 0.63 | KMO (0.39) | GLATHRBKMOKCNMA1GAA | |
| SCHEMBL83509 | 0.62 | POLB (0.53) | GLATHRBKMOGAACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158402-A1 | METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240124449-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS, INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | NOVITA PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | CORNELL UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230095474-A1 | PROCESS FOR THE PREPARATION OF LASMIDITAN | ALIVUS LIFE SCIENCES LIMITED (IN) | 2023-03-30 | — | — | US | disclosed |
| US-20230057246-A1 | NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR | LAURUS LABS LIMITED (IN) | 2023-02-23 | — | — | US | disclosed |
| US-20220009956-A1 | PREPARATION OF OLIGO CONJUGATES | EMERALD THERAPEUTICS INC (US) | 2022-01-13 | — | — | US | disclosed |
| US-11192954-B2 | Compounds and methods for the treatment of TROP2 positive diseases | BIO-THERA SOLUTIONS, LTD. (CN) | 2021-12-07 | — | — | US | disclosed |
| EP-3293175-B1 | METHODS FOR PURIFICATION OF SERINE PROTEASES | ALEXION PHARMA INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-7304163-B2 | Benzotriazole-1-yl-N-oxy phosphonium coupling agent | LUXEMBOURG INDUSTRIES LTD. (IL) | 2007-12-04 | — | — | US | disclosed |
| US-20070265265-A1 | N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070265262-A1 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2007-11-15 | — | — | US | disclosed |
| EP-1801086-A1 | Synthesis of carbon acid amides | Synthacon GmbH (DE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007070556-A2 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070600-A2 | N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007059921-A1 | SOLUTION-PHASE SYNTHESIS OF LEUPROLIDE AND ITS INTERMEDIATES | NANOKEM S.A. (UY) | 2007-05-31 | — | — | WO | disclosed |
| EP-1790656-A1 | Solution-phase synthesis of leuprolide | NANOKEM S.A. (UY) | 2007-05-30 | — | — | EP | disclosed |
| US-20070043207-A1 | Novel coupling agent and uses thereof | LUXEMBOURG INDUSTRIES LTD. (IL) | 2007-02-22 | — | — | US | disclosed |
| WO-2007020620-A1 | NOVEL COUPLING AGENT AND USES THEREOF | LUXEMBOURG INDUSTRIES LTD. (IL) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158402-A1 | METHODS FOR INHIBITING FASCIN | FSCN1, NLN, TNNI3 | GLA 1418/4885THRB 2467/4885KMO 4248/4885 |
| US-20240124449-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | GLA 1012/4885THRB 4137/4885KMO 2545/4885 |
| US-11192954-B2 | Compounds and methods for the treatment of TROP2 positive diseases | BST2, CD22, HAVCR2 | GLA 1240/4885THRB 903/4885KMO 4669/4885 |
| US-20070265262-A1 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | ZC3HAV1, HAVCR2, ZC3HAV1L | GLA 1773/4885THRB 3707/4885KMO 2633/4885 |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | GLA 1012/4885THRB 4137/4885KMO 2545/4885 |
| US-20230057246-A1 | NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR | CYP3A4, CYP4A11, CYP3A43 | GLA 1755/4885THRB 2654/4885KMO 141/4885 |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | MIF, CXCL10, CCL2 | GLA 4171/4885THRB 3719/4885KMO 4393/4885 |
| US-20070043207-A1 | Novel coupling agent and uses thereof | PTMS, ANP32A, MBTPS1 | GLA 3360/4885THRB 2502/4885KMO 3595/4885 |
| US-20230095474-A1 | PROCESS FOR THE PREPARATION OF LASMIDITAN | LPXN, TACR2, KCNH1 | GLA 1322/4885THRB 3925/4885KMO 917/4885 |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | MIF, CXCL10, CCL2 | GLA 4171/4885THRB 3719/4885KMO 4393/4885 |
| US-20070265265-A1 | N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | ZC3HAV1, ZC3HAV1L, HAVCR2 | GLA 1724/4885THRB 3531/4885KMO 2414/4885 |
| US-20220009956-A1 | PREPARATION OF OLIGO CONJUGATES | OSTC, PCBP1, PAICS | GLA 3743/4885THRB 1457/4885KMO 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.